SERA Graph | SERA PROGNOSTICS, INC.

SERA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $30.00K; Cost of revenue $50.00K; Research and development $3.49M; Operating expenses $10.03M.
2026-03-31: Revenue $14.00K; Cost of revenue $42.00K; Research and development $3.03M; Operating expenses $9.37M.
2025-12-31: Revenue $10.00K*; Cost of revenue $42.00K*; Research and development $3.22M*; Operating expenses $8.96M*.
2025-09-30: Revenue $16.00K; Cost of revenue $41.00K; Research and development $3.28M; Operating expenses $9.00M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Cost of revenue	Research and development	Operating expenses	Net income
2026-06-30	$30.00K	$50.00K	$3.49M	$10.03M	-$9.14M
2026-03-31	$14.00K	$42.00K	$3.03M	$9.37M	-$8.40M
2025-12-31	$10.00K*	$42.00K*	$3.22M*	$8.96M*	-$7.88M*
2025-09-30	$16.00K	$41.00K	$3.28M	$9.00M	-$7.81M
2025-06-30	$17.00K	$41.00K	$3.34M	$9.34M	-$8.05M
2025-03-31	$38.00K	$40.00K	$3.33M	$9.29M	-$8.19M
2024-09-30	$29.00K	$13.00K	$3.50M	$8.89M	-$7.92M
2024-06-30	$24.00K	$20.00K	$4.41M	$9.28M	-$8.30M
2024-03-31	$0.00	$17.00K	$3.68M	$9.10M	-$8.10M
2023-09-30	$42.00K	(m)	$3.54M	$8.23M	-$7.21M
2023-06-30	$123.00K	(m)	$3.69M	$11.58M	-$10.54M
2023-03-31	$100.00K	(m)	$4.10M	$11.43M	-$10.56M
2022-09-30	$87.00K	(m)	$4.18M	$11.28M	-$10.71M
2022-06-30	$78.00K	(m)	$3.26M	$11.82M	-$11.52M
2022-03-31	$38.00K	(m)	$3.32M	$12.34M	-$12.21M
2021-09-30	$23.00K	(m)	$2.72M	$9.46M	-$9.86M
2021-06-30	$20.00K	(m)	$2.82M	$7.40M	-$6.31M
2021-03-31	$13.00K	(m)	$2.40M	$6.04M	-$6.36M
2020-09-30	$5.00K	(m)	$1.89M	$4.65M	-$5.07M
2020-06-30	$6.00K	(m)	$1.75M	$4.29M	-$4.71M
2020-03-31	(m)	(m)	(m)	(m)	-$4.70M

Revenue and expense 6 month

Period end	Revenue	Cost of revenue	Research and development	Operating expenses	Net income
2026-06-30	$44.00K	$92.00K	$6.52M	$19.41M	-$17.54M
2025-06-30	$55.00K	$81.00K	$6.67M	$18.63M	-$16.23M
2024-06-30	$24.00K	$37.00K	$8.09M	$18.37M	-$16.40M
2023-06-30	$223.00K	(m)	$7.79M	$23.01M	-$21.11M
2022-06-30	$116.00K	(m)	$6.58M	$24.16M	-$23.73M
2021-06-30	$33.00K	(m)	$5.22M	$13.44M	-$12.67M
2020-06-30	$14.00K	(m)	$3.80M	$8.59M	-$9.40M

Revenue and expense 9 month

Period end	Revenue	Cost of revenue	Research and development	Operating expenses	Net income
2025-09-30	$71.00K	$122.00K	$9.96M	$27.62M	-$24.05M
2024-09-30	$53.00K	$50.00K	$11.59M	$27.27M	-$24.32M
2023-09-30	$265.00K	(m)	$11.33M	$31.24M	-$28.32M
2022-09-30	$203.00K	(m)	$10.76M	$35.44M	-$34.44M
2021-09-30	$56.00K	(m)	$7.94M	$22.90M	-$22.52M
2020-09-30	$19.00K	(m)	$5.69M	$13.24M	-$14.47M

Revenue and expense 12 month

Period end	Revenue	Cost of revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$81.00K	$164.00K	$13.17M	$36.59M	$0.00	-$31.93M
2024-12-31	$77.00K	$82.00K	$14.73M	$36.71M	$0.00	-$32.90M
2023-12-31	$306.00K	$210.00K	$15.22M	$40.13M	$0.00	-$36.24M
2022-12-31	$268.00K	(m)	$14.24M	$45.92M	$0.00	-$44.19M
2021-12-31	$82.00K	(m)	$11.02M	$35.48M	$0.00	-$35.01M
2020-12-31	$25.00K	(m)	$7.78M	$18.00M	$0.00	-$19.85M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
AMERICAN SHARED HOSPITAL SERVICES (AMS)	United States	$0.010B	-5.64
Advanced Biomed Inc. (ADVB)		$0.009B
Aclarion, Inc. (ACON)	United States	$0.008B
BioNexus Gene Lab Corp (BGLC)		$0.004B
Freenome, Inc. (FRNM)	United States	$0.143B
EXAGEN INC. (XGN)	United States	$0.212B	-5.95
BIODESIX INC (BDSX)	United States	$0.312B
Fulgent Genetics, Inc. (FLGT)	United States	$0.593B	-6.70
Lumexa Imaging Holdings, Inc. (LMRI)	United States	$0.951B
CASTLE BIOSCIENCES INC (CSTL)	United States	$1.074B	-37.45